Skip to main content
. 2021 Oct 14;28(5):4157–4166. doi: 10.3390/curroncol28050352

Figure 4.

Figure 4

Receiver operating characteristic curve analysis to identify optimal cut-off value of neutrophil-to-lymphocyte ratio (NLR) to predict response to atezolizumab + bevacizumab combination therapy (AUROC, area under the receiver operating characteristic).